Literature DB >> 23851688

Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.

Frederick L Locke1, Yuan-yuan Zha, Yan Zheng, Gregory Driessens, Thomas F Gajewski.   

Abstract

PTEN is thought to play a critical role in T cell activation by negatively regulating the PI3K signaling pathway important for cellular activation, growth, and proliferation. To directly eliminate PTEN in postthymic T cells for studies of functional effects, we used CAR transgenic × PTEN(flox/flox) mice, which enabled gene deletion using a Cre adenovirus in vitro. These mice were also immunized to generate stable Th1 clones that could have PTEN deleted when desired. PTEN-deleted T cells exhibited enhanced IL-2 production, proliferation, and Akt phosphorylation upon TCR/CD28 engagement, whereas T cell survival was not potentiated. Gene expression profiling revealed a small subset of induced genes that were augmented upon PTEN deletion. However, PTEN-deficient T cells still required CD28 costimulation for IL-2 production and remained susceptible to anti-CD3-induced anergy. The absence of PTEN within the CD8 T cell compartment led to markedly increased cytolytic activity following an allogeneic MLR in vitro, without increasing autologous MLR activity. Our results indicate that deletion of PTEN can augment the activation of postthymic T cells but does not mediate CD28 independence or anergy resistance. Nonetheless, PTEN inhibition may be a viable target for immune potentiation owing to increased cytokine production by activated CD4(+) cells and increased cytotoxicity by CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851688      PMCID: PMC3759681          DOI: 10.4049/jimmunol.1202018

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  A point mutation in CD28 distinguishes proliferative signals from survival signals.

Authors:  K Okkenhaug; L Wu; K M Garza; J La Rose; W Khoo; B Odermatt; T W Mak; P S Ohashi; R Rottapel
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

2.  Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.

Authors:  Y Y Wan; R P Leon; R Marks; C M Cham; J Schaack; T F Gajewski; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL.

Authors:  J S Burr; N D Savage; G E Messah; S L Kimzey; A S Shaw; R H Arch; J M Green
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

Review 4.  PTEN: life as a tumor suppressor.

Authors:  L Simpson; R Parsons
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

5.  The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes.

Authors:  N Nakashima; P M Sharma; T Imamura; R Bookstein; J M Olefsky
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

6.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

7.  Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.

Authors:  Yan Zheng; Yuanyuan Zha; Robbert M Spaapen; Rebecca Mathew; Kenneth Barr; Albert Bendelac; Thomas F Gajewski
Journal:  Mol Immunol       Date:  2013-03-30       Impact factor: 4.407

8.  Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines.

Authors:  L P Kane; P G Andres; K C Howland; A K Abbas; A Weiss
Journal:  Nat Immunol       Date:  2001-01       Impact factor: 25.606

9.  Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.

Authors:  A K Kacha; F Fallarino; M A Markiewicz; T F Gajewski
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  8 in total

1.  MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.

Authors:  W He; C Wang; R Mu; P Liang; Z Huang; J Zhang; L Dong
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

2.  MiR-21 controls in situ expansion of CCR6⁺ regulatory T cells through PTEN/AKT pathway in breast cancer.

Authors:  Yan Hu; Chunhong Wang; Yongju Li; Juanjuan Zhao; Chao Chen; Ya Zhou; Yijin Tao; Mengmeng Guo; Nalin Qin; Tao Ren; Zhenke Wen; Lin Xu
Journal:  Immunol Cell Biol       Date:  2015-03-04       Impact factor: 5.126

Review 3.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

4.  Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Authors:  Frederick L Locke; Meghan Menges; Anandharaman Veerapathran; Domenico Coppola; Dmitry Gabrilovich; Claudio Anasetti
Journal:  J Immunother Cancer       Date:  2015-05-19       Impact factor: 13.751

Review 5.  Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Authors:  Kamalakannan Rajasekaran; Matthew J Riese; Sridhar Rao; Li Wang; Monica S Thakar; Charles L Sentman; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2016-05-12       Impact factor: 7.561

Review 6.  The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response.

Authors:  Alberto M Martelli; Francesca Paganelli; Antonietta Fazio; Chiara Bazzichetto; Fabiana Conciatori; James A McCubrey
Journal:  Cancers (Basel)       Date:  2019-05-06       Impact factor: 6.639

7.  MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms.

Authors:  Lap Hing Chi; Ryan S N Cross; Richard P Redvers; Melissa Davis; Soroor Hediyeh-Zadeh; Suresh Mathivanan; Monisha Samuel; Erin C Lucas; Kellie Mouchemore; Philip A Gregory; Cameron N Johnstone; Robin L Anderson
Journal:  Oncogenesis       Date:  2022-07-11       Impact factor: 6.524

Review 8.  Role of inositol poly-phosphatases and their targets in T cell biology.

Authors:  Neetu Srivastava; Raki Sudan; William Garrow Kerr
Journal:  Front Immunol       Date:  2013-09-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.